PRESCRIBING FOR THE PSA AND FINALS DR FRANCESCA BONORA

Size: px
Start display at page:

Download "PRESCRIBING FOR THE PSA AND FINALS DR FRANCESCA BONORA"

Transcription

1 PRESCRIBING FOR THE PSA AND FINALS DR FRANCESCA BONORA

2 WHAT WE WILL COVER HOW TO PREPARE FOR THE PSA EXAM HOW SCENARIOS APPLY TO PRESCRIBING FOR FINALS

3 THE PSA EXAM

4 For full details of what could be asked: prescribingsafetyassessment.ac.uk/aboutpsa Click on PSA blueprint for November 2017 PDF

5 EXAMPLES OF ITEM STYLES

6 SECTION 1 PRESCRIBING Decide on the most appropriate prescription (drug, dose, route and frequency), based on the clinical circumstances Write a safe, effective and legal prescription 8 questions worth 10 marks each

7 Make sure you sign the prescriptions with your full surname (not initials) don t lose the easy marks

8 HOW TO PREPARE Exam is time pressured, so LEARN TREATMENT ALGORITHMS: Acute conditions eg acute asthma attack, acute heart failure Chronic conditions e.g. depression, reflux oesophagitis Presenting symptoms e.g. pain Find these in the back of the Oxford handbook

9 OXFORD HANDBOOK ALGORITHMS

10 THIS BOOK IS GREAT PASS THE PSA, 1E, FEB 2014, BY WILL BROWN BSC MBBS MRCP(UK) FHEA AND KEVIN W LOUDON

11 ANAPHYLAXIS TREATMENT ALGORTIHMS ACUTE ASTHMA MAKE THESE FOR YOURSELF FOR ALL COMMONEST ACUTE AND CHRONIC MEDICAL CONDITIONS PASS THE PSA, 1E, FEB 2014, BY WILL BROWN BSC MBBS MRCP(UK) FHEA AND KEVIN W LOUDON

12 HOW TO PREPARE If you can t remember use treatment summaries in the online BNF during the exam CTRL + F is your best friend!

13 BNF TREATMENT SUMMARIES CTRL + F

14 PRESCRIBING CONTROLLED DRUGS WHICH IS CORRECT? 29 Andrew Smith 01/10/87 Perrin Lecture Theatre 29 Andrew Smith 01/10/87 Perrin Lecture Theatre MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily Please supply 28 (TWENTY-EIGHT) tablets. MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily. Please supply 28 10mg (TEN MILLIGRAM) tablets.

15 PRESCRIBING CONTROLLED DRUGS WHICH IS CORRECT? 29 Andrew Smith 01/10/87 Perrin Lecture Theatre 29 Andrew Smith 01/10/87 Perrin Lecture Theatre MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily Please supply 28 (TWENTY-EIGHT) tablets. MORPHINE SULPHATE 10mg oral tablets Take one tablet, three times daily. Please supply 28 10mg (TEN MILLIGRAM) tablets. It s the total amount that you need to specify

16 PRESCRIBING CONTROLLED DRUGS Include the name and address of the patient. State the name and strength of the drug State the dose and frequency TOTAL AMOUNT must be written in WORDS AND FIGURES

17 WHAT DOSE SHOULD YOU PRESCRIBE?

18 WHAT DOSE SHOULD YOU PRESCRIBE?

19 SECTION 2 PRESCRIPTION REVIEW Identify prescriptions (drugs, doses or routes) that are inappropriate, unsafe or ineffective from amongst the current list of prescribed medicines 8 items worth 4 marks each

20 PRESCRIPTION REVIEW 11/1/17 PO FUROSEMIDE 40mg 11/1/17 PO PREDNISOLONE 40mg

21 PRESCRIPTION REVIEW 11/1/17 PO FUROSEMIDE 40mg 11/1/17 PO SHOULD BE GIVEN IN MORNING WILL KEEP PATIENT AWAKE! PREDNISOLONE 40mg SHOULD BE GIVEN IN MORNING WILL KEEP PATIENT AWAKE!

22 SPOT THE MISTAKES

23 SPOT THE MISTAKES INCORRECT DOSE SHOULD BE 62.5 MICROGRAMS WHAT TYPE? WRITE UNITS (NOT JUST U ) TECHNICALLY SHOULD BE PRESCRIBED ON THE INSULIN AREA OF THE CHART! WRITE MICROGRAMS IN FULL

24 FLUID CHART ERRORS 11/1/17 0.9% Saline 1 litre KCl 40mmol STAT A.L.S 11/1/17 Red Blood Cells 2 units hours A.L.S 11/1/17 50% Dextrose 1 litre 12 hours A.L.S

25 FLUID CHART ERRORS 11/1/17 0.9% Saline 1 litre KCl 40mmol STAT A.L.S This amount of potassium must be given over at least 4 hours due to risk of arrhythmias 11/1/17 Red Blood Cells 2 units hours A.L.S Each unit needs to be prescribed separately Has to be discarded 4 hours (from leaving the lab) 11/1/17 50% Dextrose 1 litre 12 hours A.L.S 50% Dextrose is irritant to veins. It should only be given in small volumes (20% should preferably be used if trying to reverse hypoglycaemia)

26 SECTION 3 PLANNING MANAGEMENT Deciding which treatment would be most appropriate to manage a particular clinical situation 8 items worth 2 marks each Choose most appropriate treatment from list of 5

27 COMMON ACUTE CONDITIONS KNOW THE TREATMENT ALGORITHMS FOR: STEMI NSTEMI ACUTE LEFT VENTRICULAR FAILURE TACHYCARDIA WITH PULSE ANAPHYLAXIS ACUTE ASTHMA EXACERBATION PNEUMONIA PE GI BLEED BACTERIAL MENINGITIS SEIZURE STATUS EPILEPTICUS STROKE HYPERGLYCEMIA DKA AND HHS AKI POISONING

28 COMMON CHRONIC CONDITIONS KNOW THE TREATMENT ALGORITHMS FOR: HYPERTENSION CHRONIC HEART FAILURE STROKE PREVENTION STABLE ANGINA CHRONIC ASTHMA COPD DIABETES INSOMNIA CONSTIPATION DIARRHOEA PAIN

29 SECTION 4 PROVIDING INFORMATION Decide the most important piece of information that should be provided to patients to allow them to choose whether to take the medicine and to enhance its safety and effectiveness Six items worth 2 marks

30 PROVIDING INFORMATION DRUG RAMIPRIL GLICLAZIDE METHOTREXATE WARFARIN LONG TERM STEROIDS SSRI INSULIN BISPHOSPHONATE INFORMATION STOP IN PREGNANCY TERATOGENIC EAT REGULARLY, DON T SKIP MEALS HYPO RISK REGULAR FBC NEUTROPENIA RISK MONITOR INR - BLEEDING TAKE BISPHOSPHONATE OSTEOPEROSIS RISK DON T STOP SUDDENLY CONTACT DOCTOR IF THOUGHT OF SELF HARM DOSE MAY NEED TO BE INCREASED IF UNWELL TAKE WITH FULL GLASS OF WATER AND REMAIN UPRIGHT FOR 1 HOUR

31 SECTION 5 CALCULATION SKILLS Making an accurate drug dosage calculation based on numerical information Recording answer accurately with appropriate units of measurement 8 items worth 2 marks

32 MAKE SURE YOU PRACTICE Correct number of tablets to achieve a required dose Making necessary dose adjustments based on weight or body surface area Diluting a drug for administration in an infusion pump

33 DRUG RATIOS 1% means 1g in 100ml or 10mg in 1ml for weight/volume (w/v) calculations 1g in 100g for weight/weight calculations

34 ADRENALINE RATIOS ANAPHYLAXIS 0.5mg = 0.5ml of 1 in 1,000 IM Remember 1 in 1,000 means: 1g in 1000 ml or 1000mg in 1000ml or 1ml in 1mg Therefore 0.5ml = 0.5mg CARDIAC ARREST 1mg = 10ml of 1 in 10,000 IV Remember 1 in 10,000 means: 1g in 10,000 ml or 1,000mg in 10,000ml or 1mg in 10ml

35 Dosage Calculations Always convert to the same units and then: D (What you want) H (What you ve got) x V (volume it is in) = Dose Try some practice questions:

36 SECTION 6 ADVERSE DRUG REACTIONS Likely adverse reactions to specific drugs, potentially dangerous interactions, managing adverse effects of a drug 8 items worth 2 marks each

37 ADVERSE DRUG REACTIONS THE CTRL + F SECTION Adverse effects caused by commonly prescribed drugs such as calcium channel blockers, beta2-agonists, non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics, etc. Most likely drug to have caused adverse effect e.g. renal impairment, hepatic dysfunction, hypokalaemia, urinary retention, etc. Potential interactions between medicines e.g. warfarin-statins, inhibitors NSAIDs-ACE How to treat an adverse drug reaction e.g. acute anaphylaxis, excessive anticoagulation, drug-induced hypoglycaemia, diuretic-induced dehydration etc.

38 SPOT THE POTENTIAL ADVERSE EFFECT

39 SPOT THE POTENTIAL ADVERSE EFFECT POTASSIUM BOTH DRUGS CAN CAUSE HYPERKALAEMIA

40 SPOT THE POTENTIAL ADVERSE EFFECT Some drugs causing HYPERKALAEMIA ACE Inhibitors Angiotensin Receptor Blockers (ARB) Beta Blockers Digoxin Heparin NSAIDs Spironolactone Transfusions of RBC Trimethoprim POTASSIUM BOTH DRUGS CAN CAUSE HYPERKALAEMIA

41 WHAT IS THIS PATIENT AT RISK OF?

42 WHAT IS THIS PATIENT AT RISK OF? PHENYTOIN TOXICITY Enzyme inhibitor Enzyme inducer (but relatively less so)

43 ENZYME INHIBITORS AND INDUCERS INDUCERS Increase enzyme activity Reduce drug concentration PC BRAS Phenytoin Carbamazepine Barbituates Rifampicin Alcohol (chronic excess) Sulphonylureas INHIBITORS Reduce enzyme activity Increase drug concentration AODEVICES Allopurinol Omeprazole Disulfiram Erythromycin Valproate Isoniazid Ciprofloxacin Ethanol (acute itntoxication) Sulphonamides

44 WHAT IS THIS PATIENT AT RISK OF? 11/1/17 PO OMEPRAZOLE 40mg 11/1/17 PO PAROXETINE 20mg

45 WHAT IS THIS PATIENT AT RISK OF? 11/1/17 PO 40mg 11/1/17 PO OMEPRAZOLE PAROXETINE Drugs commonly causing HYPONATRAEMIA Thiazide diuretics Amiloride Carbamazepine Sulphonylureas (but not Gliclazide) Proton pump inhibitors Antidepressants, particularly SSRIs ACE inhibitors and ARBs Opiates 20mg

46 NEPHROTOXIC & HEPATOTOXIC DRUGS NEPHROTOXIC ACE Inhibitors Aminoglycosides NSAIDs Methotrexate HEPATOTOXIC Amiodarone Isoniazid Co-amoxiclav NSAIDs Statins Anti-fungals Anti-retrovirals

47 PENICILLIN ALLERGY FLUCLOXACILLIN ERYTHROMYCIN AMIKACIN MEROPENEM CO-AMOXICLAV TAZOCIN METRONIDAZOLE RIFAMPACIN CEFTRIAXONE AVOID CAUTION SAFE

48 PENICILLIN ALLERGY

49 ALLERGIC REACTION MANAGEMENT A patient recently given Tazocin despite a Type 1 Penicillin allergy develops shortness of breath, stridor and a widespread urticarial rash. Choose 3 appropriate treatments: A) Chlorphenamine 4mg, PO B) Adrenaline 10ml of 1:10000, IV C) Adrenaline 10ml of 1:10000, IM D) Adrenaline 0.5ml of 1:1000, IV E) Adrenaline 0.5ml of 1:1000, IM F) Hydrocortisone 200mg, IV G) Chlorphenamine 10mg, IV

50 ALLERGIC REACTION MANAGEMENT A patient recently given Tazocin despite a Type 1 Penicillin allergy develops shortness of breath, stridor and a widespread urticarial rash. Choose 3 appropriate treatments: A) Chlorphenamine 4mg, PO only after resuscitation B) Adrenaline 10ml of 1:10000, IV cardiac arrest, 1mg C) Adrenaline 10ml of 1:10000, IM never used D) Adrenaline 0.5ml of 1:1000, IV never used E) Adrenaline 0.5ml of 1:1000, IM e.g. 0.5mg F) Hydrocortisone 200mg, IV G) Chlorphenamine 10mg, IV

51 SECTION 7 - DRUG MONITORING How to monitor the beneficial and harmful effects of medicines. 8 items worth 2 marks

52 DRUG LEVEL MONITORING - EXAMPLES Some detail on specific drugs: Drug Half-life Timing Toxic Level* Major Toxic Effects Gentamicin 2h Trough After 2-3 doses >2mcg/ml Nephrotoxity, irreversible ototoxicity Phenytoin 20-40h Trough After 2-3 days Total >20mcg/ml Free >2mcg/ml Nystagmus, diplopia, ataxia, confusion, hyperglycaemia Aminophylline 4-16hr N/A 4-6hrs after starting IV infusion Theophylline Trough 5 days >20mcg/ml Arrhythmias, convulsions, hypotension Digoxin 24-36h Trough 1 week >2ng/ml Arrhythmias, visual disturbance, anorexia

53 OTHER DRUG MONITORING DRUG WARFARIN LEVOTHYROXINE ACE INHIBITORS / DIURETICS CLOZAPINE ORAL CONTRACEPTION MONITOR INR TFT (CHANGE DOSE EVERY 4 WEEKS) U&Es FBC BLOOD PRESSURE

54 GENTAMICIN DOSING Hartford nomogram: guides when to give patient next dose, based on blood concentration and the time the measurement was taken E.g. if concentration is 8mg/ml, 8h after start of infusion what is correct dosing interval?

55 GENTAMICIN DOSING Hartford nomogram: guides when to give patient next dose, based on blood concentration and the time the measurement was taken Answer: 36h

56 SECTION 8 DATA INTERPRETATION Make an appropriate change to a prescription based on results of investigations 6 items worth 2 marks

57 PARACETAMOL OVERDOSE Activated charcoal: consider if >150mg/kg has been taken within a 1 hour period. N-acetylcysteine (NAC): Single overdose check level at 4h and use the nomogram (use nomogram when OD has been taken between 4-8h ago) If plasma concentration levels are above the treatment line then you need to treat Staggered overdose (>1h) cannot accurately calculate levels so treat

58 PARACETAMOL OVERDOSE E.g. Patient takes 10 paracetamol tablets at Blood test taken at Paracetamol concentration 0.4mmol/litre

59 PARACETAMOL OVERDOSE DON T TREAT

60 PRESCRIBING SCENARIOS FINALS All the same scenarios in different formats OSCES Prescribe warfarin Prescribe an IM injection eg vitamin B12 Spot the prescription errors Write fluid prescription and calculate drip rates Presenting a history and giving treatment recommendations eg hypertension WRITTEN PAPER Know your treatment algorithms for acute and chronic conditions Data interpretation questions remember side effects of drugs and how they can affect blood results

61 GOOD LUCK!!

Prescribing. Dr Andrew Smith

Prescribing. Dr Andrew Smith Prescribing Dr Andrew Smith Outline from 2014 Rules of Prescribing Prescribing Controlled Drugs Liver/Renal Disease Pregnancy/Breastfeeding Prescribing in the Elderly Allergies Adverse Drug Reactions Drug

More information

Prescribing The PSA, Finals and Beyond. Dr Andrew Smith

Prescribing The PSA, Finals and Beyond. Dr Andrew Smith Prescribing The PSA, Finals and Beyond Dr Andrew Smith Outline Plus: Some practical tips for the PSA Slides on Prescribing Theory There is a lot of overlap of knowledge which may be tested in various way

More information

Prescribing. Dr Andrew Smith

Prescribing. Dr Andrew Smith Prescribing Dr Andrew Smith Outline Rules of Prescribing Prescribing Controlled Drugs Liver/Renal Disease Pregnancy/Breastfeeding Prescribing in the Elderly Allergies Adverse Drug Reactions Drug Level

More information

PSA Tutorial. Dr Jonny Whitfield Honorary Clinical Senior Lecturer Aberdeen University Lead for PSA

PSA Tutorial. Dr Jonny Whitfield Honorary Clinical Senior Lecturer Aberdeen University Lead for PSA PSA Tutorial Dr Jonny Whitfield Honorary Clinical Senior Lecturer Aberdeen University Lead for PSA PSA Basic facts about PSA and timings Overview of each section from the PSA Blueprint with worked examples

More information

STOPP START Toolkit Supporting Medication Review in the Older Person

STOPP START Toolkit Supporting Medication Review in the Older Person STOPP START Toolkit Supporting Medication Review in the Older Person STOPP: Screening Tool of Older People s potentially inappropriate Prescriptions START: Screening Tool to Alert doctors to Right (appropriate,

More information

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

2015 Edition. Trust Medicines Formulary

2015 Edition. Trust Medicines Formulary 2015 Edition Trust Medicines Formulary Introduction Trust Medicines Formulary This formulary summarises all medicines used within the Trust, the Trust defines medicines as any substance, controlled or

More information

ECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic

ECX. Anti-emetics: Day 1: highly emetogenic Days 2 21: mildly emetogenic Page 1 of 5 As an alternative to ECF: For locally advanced (inoperable) or metastatic oesophageal or gastric cancer; peri-operative use in oesophageal or gastric cancer; adenocarcinoma of unknown primary

More information

Drug Prescribing. Ravi Menon

Drug Prescribing. Ravi Menon Drug Prescribing Ravi Menon Introduction Approximately 7,000 individual drug doses are administered each day in a 'typical' NHS hospital, 70% of which are prescribed by first year graduates and senior

More information

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)

MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab

More information

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre.

Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Aspirin poisoning CLINICAL FEATURES Salicylates commonly cause tinnitus, deafness, nausea and vomiting (salicylism). Hyperventilation results from stimulation of respiratory centre. Severe poisoning causes

More information

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin

Antibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Antibiotic Class Interacting Drug Comment Penicillins Methotrexate Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Cephalosporins Cefaclor Cefixime Cefuroxime Cephalexin Cefazolin* Ceftriaxone*

More information

Carboplatin + Paclitaxel Cancer of the Cervix

Carboplatin + Paclitaxel Cancer of the Cervix Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they

More information

Cisplatin / Paclitaxel Gynaecological Cancer

Cisplatin / Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual

More information

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and

More information

What is Hypertension?

What is Hypertension? What is Hypertension? What is hypertension? Hypertension is also known as high blood pressure. Our blood needs to be under pressure to make it move around the body, but when it is too high this causes

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical

More information

Back to Basics: The Basics of Medication Monitoring

Back to Basics: The Basics of Medication Monitoring DIAMOND PHARMACY SERVICES Back to Basics: The Basics of Medication Monitoring Presented by: Dr. Deborah Milito, Pharm. D., CGP. Director of Clinical and Consultant Services Skilled Division Annual Educational

More information

Appendix 5: Hepatic impairment

Appendix 5: Hepatic impairment Appendix 5: Hepatic impairment Liver disease may alter the response to drugs. However, the hepatic reserve appears to be large and liver disease has to be severe before important changes in drug metabolism

More information

DR J HARTY / DR CM RITCHIE / DR M GIBBONS

DR J HARTY / DR CM RITCHIE / DR M GIBBONS CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Paracetamol Poisoning DR J HARTY / DR CM RITCHIE / DR M GIBBONS Medicine Acute Date Uploaded: 16 th September 2014 Review Date

More information

PATIENT INFORMATION LEAFLET PEARINDA PLUS

PATIENT INFORMATION LEAFLET PEARINDA PLUS SCHEDULING STATUS OF THE MEDICINAL PRODUCT S3 NAME OF MEDICINAL PRODUCT 2 (Tablet) 4 (Tablet) Read this leaflet carefully before you start taking. Keep this leaflet. You may need to read it again. If you

More information

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy

Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy 1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer

More information

Understanding your take home medications from the surgical ward. Information for Patients

Understanding your take home medications from the surgical ward. Information for Patients Understanding your take home medications from the surgical ward Information for Patients i Information for Patients Please read this leaflet before taking the medications that have been prescribed for

More information

Cisplatin and Pemetrexed (NSCLC, mesothelioma)

Cisplatin and Pemetrexed (NSCLC, mesothelioma) Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as

More information

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations Chapter 3 Cardiology Georgia Woodfield ASPIRIN FONDAPARINUX 300 once only in acute MI 75 in primary/ secondary prevention of thrombus formation and thromboembolic disease or PR; can also be given via nasogastric

More information

Appendix 1: Interactions

Appendix 1: Interactions Appendix 1: Interactions Two or more drugs given at the same time may interact with each other. The interaction may be potentiation or antagonism of one drug by another, or occasionally some other. Drug

More information

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage

More information

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes. R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg

More information

DRUGS FOR VIVA. IAP UG Teaching slides

DRUGS FOR VIVA. IAP UG Teaching slides DRUGS FOR VIVA 1 Q:1 INJ SODIUM BICARBONATE 1. What all strengths are available? 2. What are the clinical indications for IV sodium bicarbonate? 3. How do you administer this drug? 2 ANS: 1. Available

More information

LET - Maths, Stats & Numeracy

LET - Maths, Stats & Numeracy Metric Conversions Here are some metric weights arranged in size order, starting with the biggest:- Kg (kilogram) g (gram) mg (milligram) mcg (microgram) Each one is a thousand (1000) times smaller than

More information

(R) CODOX M / (R) IVAC

(R) CODOX M / (R) IVAC (R) CODOX M / (R) IVAC Indication Burkitt's or Burkitt's-like lymphoma, especially those with 1 or more of the following poor risk criteria: - Raised LDH level - WHO performance status 2-4 - Ann Arbor

More information

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1.

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1. Systemic Anti-Cancer Treatment Protocol Abiraterone PROCTOCOL REF: MPHAABIRA (Version No: 1.0) Approved for use in: The treatment of metastatic castration resistant prostate cancer in adult men who are

More information

Cisplatin / 5-Fluorouracil for Vulval Cancer

Cisplatin / 5-Fluorouracil for Vulval Cancer Cisplatin / 5-Fluorouracil for Vulval Cancer Indication: Palliative therapy in patients with Vulval Cancer Regimen details: Cisplatin 75mg/m 2 (*) IV 5-Fluorouracil (5-FU) 1000mg/m 2 /24 hours IV D4 (*)Consider

More information

Cardiac Catheter Labs Intravenous Drug Therapy Guide

Cardiac Catheter Labs Intravenous Drug Therapy Guide Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab

More information

sulfonamide antibiotics

sulfonamide antibiotics Appropriate use of sulfonamide antibiotics What are sulfonamides and how do they work? Sulfonamides are a group of synthetic medicines that contain the sulfonamide chemical group. As well as antibiotics,

More information

Antiallergics and drugs used in anaphylaxis

Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis The H 1 -receptor antagonists are generally referred to as antihistamines. They inhibit the wheal, pruritus, sneezing

More information

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck

Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Cisplatin100 plus Radiotherapy for locally Advanced Squamous Cell Carcinoma Head and Neck Indication: 1) Concomitant chemo-radiotherapy for locally advanced squamous cell carcinoma head and neck 2) Post-operative

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal

More information

Cisplatin and Gemcitabine (bladder)

Cisplatin and Gemcitabine (bladder) Cisplatin and Gemcitabine (bladder) Indication Palliative therapy for locally advanced or metastatic bladder cancer in patients with good renal function. Palliative therapy for urothelial transitional

More information

Get Healthy Stay Healthy

Get Healthy Stay Healthy Hypertension Management WHAT IS HYPERTENSION (HIGH BLOOD PRESSURE)? Blood pressure is a measure of how hard the blood pushes against the walls of your arteries as it moves through your body. It is normal

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Perfan Injection 100 mg/20 ml Concentrate for Solution for Injection Active substance: enoximone Read all of this leaflet carefully before you

More information

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

Top tips for surviving your first on call Dr Maleeha Rizvi

Top tips for surviving your first on call Dr Maleeha Rizvi Top tips for surviving your first on call Dr Maleeha Rizvi Specialist Registrar in Cardiology University Hospital Lewisham Overview Practical points The Bleep and prioritising on call Cardiac arrests Prescribing

More information

Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer

Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer Cisplatin / 5-Fluorouracil (+ Trastuzumab) in Gastric Cancer Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. For Trastuzumab doses

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) CP11 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION The

More information

Using the BNF. CWFS F1 Programme Safe Prescribing Module

Using the BNF. CWFS F1 Programme Safe Prescribing Module Using the BNF CWFS F1 Programme Safe Prescribing Module Know Your BNF Guidance on prescribing - Controlled drugs and dependence - Prescribing in palliative care/elderly/children Emergency treatment of

More information

UNIVERSITY OF BOLTON SCHOOL OF HEALTH AND HUMAN SCIENCES BSC (HONS) PRE-REGISTRATION NURSING EDUCATION (ADULT) SEMESTER ONE EXAMINATION 2016/17

UNIVERSITY OF BOLTON SCHOOL OF HEALTH AND HUMAN SCIENCES BSC (HONS) PRE-REGISTRATION NURSING EDUCATION (ADULT) SEMESTER ONE EXAMINATION 2016/17 LJW3 UNIVERSITY OF BOLTON SCHOOL OF HEALTH AND HUMAN SCIENCES BSC (HONS) PRE-REGISTRATION NURSING EDUCATION (ADULT) SEMESTER ONE EXAMINATION 2016/17 FOUNDATIONS OF MEDICINES MANAGEMENT MODULE CODE: HLT4085

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful

More information

Module. Module. Managing Other Chronic Conditions. Managing Other Chronic Conditions

Module. Module. Managing Other Chronic Conditions. Managing Other Chronic Conditions Managing Other Chronic Conditions 8 Managing Other Chronic Conditions Taking Control of Heart Failure Important Information Please write down important contact information in the space below. You may also

More information

Flecainide BNM. Please read this leaflet carefully before you start taking Flecainide BNM.

Flecainide BNM. Please read this leaflet carefully before you start taking Flecainide BNM. 1 Consumer Medicine Information Flecainide acetate Tablets 50 mg & 100 mg What is in this leaflet Please read this leaflet carefully before you start taking. This leaflet answers some common questions

More information

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix

Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Cisplatin + Etoposide IV / Oral therapy followed by Chemo-radiotherapy in Small Cell Carcinoma of the Cervix Indication: Neoadjuvant chemotherapy followed by Chemo-radiotherapy in Small Cell Carcinoma

More information

2. Adverse Drug Reactions

2. Adverse Drug Reactions 2. Adverse Drug Reactions Background Medicines Information Centres receive many enquiries specifically about adverse drug reactions (ADRs), as well as a large number featuring related patient safety issues

More information

NEXIUM INTRAVENOUS esomeprazole sodium

NEXIUM INTRAVENOUS esomeprazole sodium NEXIUM INTRAVENOUS esomeprazole sodium Consumer Medicine Information What is in this leaflet This leaflet answers some of the common questions people ask about NEXIUM Intravenous (IV). It does not contain

More information

Name Date Period. West Nomogram

Name Date Period. West Nomogram West Nomogram A West Nomogram is used to help adjust medication calculations for children. Because children are smaller than adults, they are usually given smaller amounts of medication. The adjustment

More information

PRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas

PRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas PRESCRIBING IN THE ELDERLY CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas LEARNING OUTCOMES Medicines Optimisation The effects of aging on health and medicines. Polypharmacy Acute Kidney

More information

ADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments

ADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments ADENOSINE Paroxysmal SVT 1 st Dose 6 mg rapid IV 2 nd & 3 rd Doses 12 mg rapid IV push Follow each dose with rapid bolus of 20 ml NS May cause transient heart block or asystole. Side effects include chest

More information

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour

TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour TIP: Paclitaxel / Ifosfamide / Cisplatin in Relapsed Germ Cell Tumour Indication: Second line therapy in Relapsed Germ Cell Tumours Regimen details: Paclitaxel 175mg/m 2 IV Cisplatin 20mg/m 2 IV - D5 Ifosfamide

More information

ACETYLCYSTEINE INJECTION

ACETYLCYSTEINE INJECTION ACETYLCYSTEINE INJECTION 1. Name of the medicinal product Acetylcysteine 200 mg/ml Injection 2. Qualitative and quantitative composition Acetylcysteine 200mg per ml (as N-acetylcysteine) Each 10ml ampoule

More information

(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.

(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab. (R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell

More information

Drug Max dose approved for IVP Dilution Rate Monitoring Parameters. Dilution not necessary (Available in prefilled syringe)

Drug Max dose approved for IVP Dilution Rate Monitoring Parameters. Dilution not necessary (Available in prefilled syringe) Drug Max dose approved for IVP Dilution Rate Monitoring Parameters Acetazolamide 500 mg Reconstitute with at least 5ml sterile water (max concentration should not exceed 100mg/ml) 100-500 mg/min Hypotension

More information

Prescribing and Administration of Analgesia within Maternity

Prescribing and Administration of Analgesia within Maternity Prescribing and Administration of Analgesia within Maternity CONTENTS Introduction and Who The Guideline Applies To... 2 UHL Paracetamol Prescribing Guideline... 2 Oral dosing... 2 Intravenous dosing...

More information

BACTRIM tablets PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1 WHAT BACTRIM IS AND WHAT IT IS USED FOR

BACTRIM tablets PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1 WHAT BACTRIM IS AND WHAT IT IS USED FOR PACKAGE LEAFLET: INFORMATION FOR THE USER BACTRIM tablets CO-TRIMOXAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

Appendix 4: Renal impairment

Appendix 4: Renal impairment Appendix 4: Renal impairment Reduced renal function may cause problems with drug therapy for the following reasons: 1. The failure to excrete a drug or its metabolites may produce toxicity. 2. The to some

More information

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES

CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION

More information

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018

Patient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version

More information

TIP Paclitaxel, Ifosfamide and Cisplatin

TIP Paclitaxel, Ifosfamide and Cisplatin Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage

More information

Guidelines for Medicines Optimisation in Patients with Acute Kidney Injury

Guidelines for Medicines Optimisation in Patients with Acute Kidney Injury Guidelines for Medicines Optimisation in Patients with Acute Kidney Injury Publication July 2016 Guidelines for Medicines Optimisation in Patients with Acute Kidney Injury Review date February 2018 Table

More information

PATIENT MEDICATION INFORMATION

PATIENT MEDICATION INFORMATION - 1 - READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION TENORMIN atenolol tablets Read this carefully before you start taking TENORMIN and each time you get a refill.

More information

Southern Derbyshire Shared Care Pathology Guidelines. Hyponatraemia in Adults

Southern Derbyshire Shared Care Pathology Guidelines. Hyponatraemia in Adults Southern Derbyshire Shared Care Pathology Guidelines Hyponatraemia in Adults Purpose of Guideline The investigation and management of adult patients with newly diagnosed hyponatraemia. Hyponatraemia can

More information

Clinical Pharmacology and Prescribing

Clinical Pharmacology and Prescribing 1 Clinical Pharmacology and Prescribing Dr Susannah O Sullivan Department of Pharmacology 2 Objectives Recognise the importance of clinical pharmacology as the scientific discipline that underpins a rational

More information

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes

More information

Medication Calculations - part 1

Medication Calculations - part 1 Medication Calculations - part 1 Learning Skills Introduction: Common calculations required in nursing include finding volumes needed for oral or injected doses and working out IV infusion flow and drip

More information

Prescribing in the Elderly. Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry

Prescribing in the Elderly. Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry Prescribing in the Elderly Dr Alison Macrae and Dr Debbie Vest GPST2 Drs in Psychiatry 24 th September 2014 Objectives Understand the significance of polypharmacy in the elderly Become familiar with the

More information

PHARMACOLOGY AND PHARMACOKINETICS

PHARMACOLOGY AND PHARMACOKINETICS DRUG GUIDELINE Insulin, human neutral (Actrapid ) Intravenous Infusion for SCOPE (Area): FOR USE IN: Critical Care Unit, Emergency Department and Operating Suite EXCLUSIONS: Paediatrics (seek Paediatrician

More information

CABAZITAXEL Prostate Cancer

CABAZITAXEL Prostate Cancer Systemic Anti-Cancer Treatment Protocol CABAZITAXEL Prostate Cancer PROCTOCOL REF: MPHACABAZ (Version No: 1.0) Approved for use in: Cabazitaxel in combination with prednisolone is a treatment option for

More information

Chapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given

Chapter 5 Gastroenterology. Dose. Route. Units. Given. Dose. Route. Units. Given Chapter 5 Gastroenterology Georgia Woodfield TERLIPRESSIN CIPROFLOXACIN 2 initial dose 500 Every 4 hours until bleeding controlled can be reduced to 1 after initial dose if side effects develop or if patient

More information

PACKAGE LEAFLET: Information for the patient FUROSEMID Tablets - 40 mg Solution for injection - 20 mg / 2 ml (Furosemide)

PACKAGE LEAFLET: Information for the patient FUROSEMID Tablets - 40 mg Solution for injection - 20 mg / 2 ml (Furosemide) PACKAGE LEAFLET: Information for the patient FUROSEMID Tablets - 40 mg Solution for injection - 20 mg / 2 ml (Furosemide) Read this leaflet carefully before you start taking this medicine. - Keep this

More information

Adrenaline 1mg in 10mL (1:10,000) Pre-filled syringe 3 Amiodarone 300mg/10mL Pre-filled syringe 5

Adrenaline 1mg in 10mL (1:10,000) Pre-filled syringe 3 Amiodarone 300mg/10mL Pre-filled syringe 5 Quick Reference Guide for: Cardiac Arrest Medicines Box (BLUE) Please Note: Any medicines given must form part of an Airway, Breathing, Circulation, Disability and Exposure (ABCDE) Assessment (9)999 must

More information

Elements for a Public Summary Overview of disease epidemiology

Elements for a Public Summary Overview of disease epidemiology VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other

More information

Refer to the manufacturers prescribing information or instructions for use before taking any medications.

Refer to the manufacturers prescribing information or instructions for use before taking any medications. Medicines Medicines play an important role in treatment for patients who have had a heart attack or who have heart failure. In most cases, people who have had a heart attack or who have heart failure require

More information

EDEMID FORTE 500mg tablets

EDEMID FORTE 500mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER EDEMID FORTE 500mg tablets FUROSEMIDE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

Our Commitment to Quality and Patient Safety Core Measures

Our Commitment to Quality and Patient Safety Core Measures Calvert Memorial Hospital is committed to our community, with a focus on patient-centered care. High quality and safe patient care is not our goal, it is our priority. That means delivering the best possible

More information

Panobinostat, Bortezomib and Dexamethasone

Panobinostat, Bortezomib and Dexamethasone Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory

More information

Cisplatin and Fluorouracil

Cisplatin and Fluorouracil Cisplatin and Fluorouracil Indication Neo-adjuvant treatment of nasopharyngeal head and neck cancer (stage II-IV) or bulky disease at other head and neck sites. Performance Status 0-1 ICD-10 codes Codes

More information

Gemcitabine, Carboplatin and Bevacizumab (gynae)

Gemcitabine, Carboplatin and Bevacizumab (gynae) Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10

More information

Geri-PARDY! (2015 Beers Criteria) Pharmacology Edition

Geri-PARDY! (2015 Beers Criteria) Pharmacology Edition Geri-PARDY! Pharmacology Edition (2015 Beers Criteria) Aurelio Muyot, MD, AGSF, FACP Assistant Professor College of Osteopathic Medicine Touro University Nevada Objectives Review the 2015 Beers Criteria

More information

It does not contain all the available information. It does not take the place of talking to your doctor or nurse.

It does not contain all the available information. It does not take the place of talking to your doctor or nurse. DYNASTAT (die-na-stat) parecoxib Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Dynastat powder for injection. It does not contain all the available

More information

ELECTROLYTES RENAL SHO TEACHING

ELECTROLYTES RENAL SHO TEACHING ELECTROLYTES RENAL SHO TEACHING Metabolic Alkalosis 2 factors are responsible for generation and maintenance of metabolic alkalosis this includes a process that raises serum bicarbonate and a process that

More information

Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride

Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride PACKAGE LEAFLET: INFORMATION FOR THE USER Dialosa 1 mg, 2 mg, 3 mg, 4 mg and 6 mg tablets Glimepiride Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may

More information

GLUCOPHAGE 500 mg mg mg

GLUCOPHAGE 500 mg mg mg GLUCOPHAGE 500 mg - 750 mg - 1000 mg Prolonged release tablets metformin hydrochloride This medicine is intended for adult patients only Read all of this leaflet carefully before you start taking this

More information

5 MUSCULOSKELETAL SYSTEM

5 MUSCULOSKELETAL SYSTEM 5 MUSCULOSKELETAL SYSTEM 5.01 NON-STEROIDAL ANTIILAMMATORY DRUGS (NSAIDS) *Acetylsalicylic Acid (Aspirin) Tab Soluble 300mg Diclofenac Sodium Tab 25mg, Supp 25mg, 50mg & 100mg (Voltaren) 300-900mg every

More information

STOPP and START criteria October 2011

STOPP and START criteria October 2011 # START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which

More information

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*

More information

Carboplatin, Paclitaxel and Bevacizumab (gynae)

Carboplatin, Paclitaxel and Bevacizumab (gynae) Carboplatin, Paclitaxel and Bevacizumab (gynae) Indication First line treatment of recurrent or metastatic cervical cancer. WHO performance status 0 or 1. First line treatment of advanced epithelial ovarian,

More information

CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX

CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion

More information